Telemonitoring Impact by the ApTelecare Software in Dialysis Patient

Tmm Software72 enrolled

Overview

The investigators proposed to conduct a retrospective study to evaluate the impact of the implementation of apTeleCare software on the management of dialysis patients at home in terms of the number and duration of hospitalizations. For this purpose, the investigators will compare patients' data over a 2-year interval before the introduction of Telemonitoring (January 2012 and December 2013 inclusive - Group 1) with patients data who have benefited from this application (between August 2016 and July 2018).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Renal Failure Dialysis Related Complication

Interventions

Telemonitoring SoftwareDEVICE

Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (≥ 18 years) with no age limit; * Patients receiving peritoneal dialysis on the investigation center between 2012 and 2014 (Group1) and between 2016 and 2018 (Group 2); * Patient information in this retrospective study; Exclusion Criteria: * Patients who have started a peritoneal dialysis program before the periods of investigation; * Patients who have been equipped with apTeleCare during the dialysis program; * Subject under guardianship, curators or safeguard of justice; * Patient not affiliated to a French social protection;

Locations (1)

Matthieu Merlot

Montpellier, France

Outcomes

Primary Outcomes

Cumulative duration (on retrospective two years of follow-up) of the unscheduled hospitalizations between the two patient groups.

Time frame: up to two years.

Cumulative duration (on retrospective two years of follow-up) of the scheduled hospitalizations between the two patient groups.

Time frame: up to two years.

Secondary Outcomes

Total length of hospitalisation

Time frame: For both groups. Every two months (follow-up visit) on a retrospective period of two years, the outcome 2 will be measured. The study duration will be of 5 months

Number of events of cardiovascular complications

Time frame: For both groups. Every two months (follow-up visit) on a retrospective period of two years. The study duration will be of 5 months

Mortality rate

Time frame: For both groups. At the end of this retrospective study (Study Period of 5 months).

Rate of peritoneal infections

Time frame: For both groups. At the end of this retrospective study.(Study Period of 5 months).

Number of patient exit technique except death

For example transplant, hemodialysis

Time frame: For both groups. At the end of this retrospective study. (Study Period of 5 months).

Charlson score : Comorbidity index

This scale measure the comorbidity symptoms of patients at the beginning of the care by the physician. The minimum score will be "0" and the maximum will be 39. Its validation is based on a prediction of health French insurance, as well as on several clinical areas such as oncology or nephrology.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.